Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.32% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates

NuStar Energy

RMR Group

Spirit Airlines

Waters

Although, expectations for fourth-quarter 2019 earnings are negative at present, results so far are far better than initially anticipated.

5 Top Stocks Set to Beat Earnings Estimates Next Week

Covanta Holding Corp

HealthEquity

SailPoint Technologies Hlds

Zumiez

These top-ranked stocks are likely to beat on bottom line in their next releases.

Bet on Earnings Beat With 5 Top-Ranked Stocks

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks

Neurocrine Knocked Back On Ingrezza Concerns And Maybe The Lack Of A Buyout

Amneal Pharmaceuticals

AMRX vs. NBIX: Which Stock Is the Better Value Option?

Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?

Biogen

Bristol-Myers

Eli Lilly

Regeneron Pharmaceuticals

Sarepta Therapeutics

If biotech stocks were red hot at the end of 2019, expect them to be scorching next week.

Red-Hot Biotech Stocks Brace For Key Meeting — Here's What To Expect

Rapid sales growth for its tardive dyskinesia drug fueled investor optimism.

Why Neurocrine Biosciences Soared 50.5% in 2019

ABIOMED

ACADIA Pharma

Accelerate Diagnostics

DexCom

Exact Sciences

Jazz Pharmaceuticals

NeoGenomics

Repligen

Simulations Plus

The 10 Best Healthcare Stocks of the Decade

Domino's Pizza

Netflix

Novanta

Here's your proof for taking a long-term approach to investing.

The Five Best Stocks of the Past Decade

Amazon

Broadcom

The 2010s were a fruitful decade for investors as the S&P 500 has surged over 189% so far.

3 Breakout Stocks of the Last Decade to Consider for 2020

Karuna Therapeutics Inc

Minerva Neurosciences

4 Biotech Neurology Stocks, As Biotechs March On

Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Neurocrine Bounces Back With Authority, But Little Upside Appears Evident As New Year Approaches

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2019 Results - Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates

Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)

Catalent

CTLT vs. NBIX: Which Stock Is the Better Value Option?

CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

CTLT or NBIX: Which Is the Better Value Stock Right Now?

HKMPF vs. NBIX: Which Stock Is the Better Value Option?

HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?

Neurocrine (NBIX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Neurocrine (NBIX) Could Be Positioned for a Surge

Ingrezza sales came in well ahead of expectations as management continues to execute well with its commercial launch in this under-penetrated market.

Neurocrine Executing Very Well With Its Lead Commercial Compound

Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Neurocrine (NBIX) Might be Well Poised for a Surge

Sales soared for the drug Ingrezza. And key pipeline developments are on the way.

News for Neurocrine Biosciences Stock (NBIX)